Ipsen IPN.PA
Ipsen is a global biopharmaceutical company focused on oncology, rare diseases, and neuroscience, commercializing innovative medicines with a growth model based on selective acquisitions and internal development. Ipsen shows solid fundamentals with net cash (ND/EBITDA -0.68), high margins (gross margin 81.01%) and strong growth (revenue +18.7%), but the entry of a generic in the US for a key product introduces a material risk that has already hit the stock.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Ipsen is a global biopharmaceutical company focused on oncology, rare diseases, and neuroscience, commercializing innovative medicines with a growth model based on selective acquisitions and internal development. Ipsen shows solid fundamentals with net cash (ND/EBITDA -0.68), high margins (gross margin 81.01%) and strong growth (revenue +18.7%), but the entry of a generic in the US for a key product introduces a material risk that has already hit the stock.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.6 |
| Quality / Moat | 7.7 |
| Valuation | 7.4 |
| Growth | 7.5 |
| Dividend | 5.2 |
| Momentum | 8.3 |
| Risk & Context | 7.7 |
OVERALL SCORE: 7.6/10
Context and risks
Regulatory and market risk from the entry of a generic in the US for a key product (somatuline), which has already caused a drop in the stock. Dependence on product exclusivity in a competitive market is the main risk.
News considered in the analysis
- Ipsen Shares Fall After Early Launch of U.S. Generic Rival — La entrada temprana de un genérico para un producto clave (hormona) erosiona ingresos y márgenes; el impacto ya está parcialmente en el precio tras la caída de la acción.
- AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod — La aprobación de la FDA al genérico de Amneal confirma la competencia inminente; refuerza el riesgo de pérdida de exclusividad.
- Ipsen (ENXTPA:IPN) Could Be 11% Undervalued Following Board Changes — Análisis de valoración de Simply Wall St. sin información nueva; ruido.
- European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance — Artículo sectorial sobre competitividad europea; sin impacto directo en Ipsen.
- European drugmakers call for faster trials, more spending to compete with US, China — Llamamiento sectorial a la UE; sin efecto inmediato en los fundamentales de Ipsen.
Verdict: Hold; the attractive valuation (forward P/E 10.34) partially compensates for the loss-of-exclusivity risk, but the market share evolution of the affected product should be monitored.
Main risk: The entry of a generic in the US for a key product (hormone) that could significantly erode revenue and margins in the coming quarters.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →